September 21, 2023 01:11 PM EDTUpdated September 22, 04:35 AM
Cell/Gene Tx
Manufacturing

Q&A: No­vo Nordisk Foun­da­tion’s Celler­a­tor CEO Thomas Carlsen digs in­to $135.4M Dan­ish cell ther­a­py fa­cil­i­ty

Anna Brown

News Reporter

The No­vo Nordisk Foun­da­tion re­vealed Thurs­day it has com­mit­ted €127 mil­lion ($135.4 mil­lion) to build a new cell ther­a­py fa­cil­i­ty in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times